The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued

Journal of Hepatology

Volumn 54, Issue 2, 2011, Pages 395-396

  Buster, Erik H C J ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; VIRUS DNA;

ETHNICITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

GENOTYPE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 78751575977     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.07.052     Document Type: Letter

References (12)

1. S. Raimondi, P. Maisonneuve, S. Bruno, and M.U. Mondelli Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 52 2010 441 449
2. F. Bonino, P. Marcellin, G.K. Lau, S. Hadziyannis, R. Jin, and T. Piratvisuth Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 2007 699 705
3. G. Cooksley, G.K.K. Lau, Y.F. Liaw, P. Marcellin, W.C. Chow, and S. Thongsawat Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomised study J Hepatol 42 2005 S30
4. A. Craxi, D. Di Bona, and C. Camma Interferon-alpha for HBeAg-positive chronic hepatitis B J Hepatol 39 2003 S99 S105
5. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
6. E.H. Buster, B.E. Hansen, G.K. Lau, T. Piratvisuth, S. Zeuzem, and E.W. Steyerberg Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2009 2002 2009
7. E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
8. R.N. Chien, C.T. Yeh, S.L. Tsai, C.M. Chu, and Y.F. Liaw Determinants for sustained HBeAg response to lamivudine therapy Hepatology (Baltimore, Md.) 38 2003 1267 1273
9. M. Buti, M. Cotrina, A. Valdes, R. Jardi, F. Rodriguez-Frias, and R. Esteban Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 36 2002 445 446
10. Y. Lurie, M.P. Manns, R.G. Gish, T.T. Chang, C. Yurdaydin, and C.L. Lai The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B J Hepatol 42 2005 184
11. M.F. Yuen, D.K. Wong, E. Sablon, H.J. Yuan, S.M. Sum, and C.K. Hui Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine Antivir Ther 8 2003 531 534
12. E.H. Buster, B.E. Hansen, E. Verhey, R.A. De Man, and H.L. Janssen HBV genotype is an important predictor of sustained off-treatment response to both peginterferon alpha-2b and entecavir in HBeAg positive chronic hepatitis B Hepatology (Baltimore, MD) 48 2008 716A